Three immunizations with a bivalent human papillomavirus (HPV)-16/18 L1 virus-like particle AS04 vaccine safely induces sustained high levels of antibodies that provide long-term protection against HPV-16 and -18 infection and associated cervical lesions and possibly against HPV 45 and HPV 31-the third and fourth most common HPV types associated with cervical cancer-for up to 4.5 years.
Three immunizations with a bivalent human papillomavirus (HPV)-16/18 L1 virus-like particle AS04 vaccine safely induces sustained high levels of antibodies that provide long-term protection against HPV-16 and -18 infection and associated cervical lesions and possibly against HPV 45 and HPV 31-the third and fourth most common HPV types associated with cervical cancer-for up to 4.5 years.
The information comes from follow-up data from a randomized, multicenter, double-blind, placebo-controlled trial paid for and coordinated by the manufacturer of the vaccine. The findings put the vaccine one step closer to widespread use and prevention of cervical cancer.
The authors of the data found that more than 98% seropositivity was maintained for HPV-16 and -18 during the extended follow-up period. In terms of its efficacy with various HPV-16 and HPV-18 endpoints, the vaccine was 96.9% effective against incident infection, 94.3% effective against the 6-month definition of persistent infection, 100% effective against the 12-month definition of persistent infection, and 100% effective against cervical intraepithelial neoplasia lesions associated with the vaccine types.
Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
Link between prenatal air pollution and reduced lung function in offspring reported
July 25th 2024Higher prenatal exposure to PM2.5 pollution is associated with reduced lung volume and airflow limitation in children, highlighting the critical impact of air pollution on in utero lung development.
Read More
Cut costs observed from out-of-home care in children with prenatal substance exposure
July 24th 2024A recent study reveals that while children exposed to maternal substance use face higher hospital costs up to age 20 years, out-of-home care significantly mitigates this financial burden.
Read More
Global progress in neonatal tetanus elimination from 2000 to 2022
July 18th 2024Incorporating maternal and neonatal tetanus elimination strategies into national immunization activities is crucial for sustaining elimination and reducing neonatal mortality worldwide, as highlighted by the latest CDC report.
Read More
PreTRM test shows efficacy in reducing severe neonatal morbidity and mortality
July 18th 2024The PreTRM test, a blood-based biomarker test for predicting preterm birth risk, has demonstrated significant efficacy in lowering severe neonatal morbidity and mortality, as reported by Sera Prognostics Inc.
Read More